Advertisement

Topics

Laboratorios Farmacéuticos ROVI (ROVI) - Biosimilar enoxaparin launches

06:23 EST 14 Nov 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Laboratorios Farmacéuticos ROVI: ROVI reported operating revenue of €203m for 9M17 (+ 6%), driven by exceptionally strong growth in the toll manufacturing business (+20%). The speciality pharmaceutical business grew 3%, aided by sales growth in newer product launches offsetting declines in the mature portfolio. ROVI has launched its internally developed biosimilar enoxaparin into the first European market (Germany) ahead of any competition; this is a key driver of sales and operating growth in the medium term. R&D progress continues with the long-acting DORIA (schizophrenia) and letrozole (breast cancer) having entered Phase III and Phase I of clinical-stage development respectively. Our revised valuation is €0.98bn.
ISIN: ES0157261019

Original Article: Laboratorios Farmacéuticos ROVI (ROVI) - Biosimilar enoxaparin launches

NEXT ARTICLE

More From BioPortfolio on "Laboratorios Farmacéuticos ROVI (ROVI) - Biosimilar enoxaparin launches"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...